368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors

368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors

Bibliographic Details
Main Authors: Anh Nguyen, Adi Diab, Brendan Curti, Jonathan Zalevsky, Mary Tagliaferri, Christie Fanton, Evidio Domingo-Musibay, Wei Lin, Mehmet Bilen, Sandra D’Angelo, Andrew Brohl, Erkut Borazanci, Cat Haglund, Mona Vimal, Mann Muhsin, Mario Marcondes
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items